Prognostic and predictive factors in breast cancer

Voprosy Onkologii

Volumn 51, Issue 4, 2005, Pages 434-443

  Bozhok, A A ^a   Semiglazov, V F ^a   Semiglazov, V V ^b   Arzumanov, A S ^c   Kletsel, A E ^d  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Russian Center for Research in Radiological and Surgical Technologies   (Russian Federation)

^d Clinic of Oncology and Gynecology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29844438360     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Aas T., Geisler S., Eide G.E. et al. Predictive value of tumor cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy // Europ. J. Cancer.-2003.-Vol. 39.-P. 438-446.
2. Allred D.C., Clark G.M., Tandon A.K. et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma // J. Clin. Oncol. - 1992. - Vol. 10. - P. 599-605.
3. Amat S., Penault-Llorca F., Cure H. et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosenstivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy // Int. J. Oncol. - 2002. - Vol. 20. - P. 791-796.
4. Anelli A., Brentani R.R., Gadelha A.P. et al. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer // Ann. Oncol. - 2003. - Vol. 14. - P. 1156.
5. Bonetti A., Zaninelli M., Leone R. et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer // Clin. Cancer Res. - 1998. - Vol. 4. - P. 2331-2336.
6. Bonnefoi H., Diebold-Berger S., Therasse P. et al. Locally-advanced inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?//Ann. Oncol. - 2003. - Vol. 14. - P. 406-413.
7. Bottini A., Berruti A., Bersiga A. et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients // Clin. Cancer Res. - 2000. - Vol. 6. - P. 2751-2758.
8. Bottini A., Berruti A., Brizzi M.P. et al. Single agent epirubicin versus the combination epirubicin plus tamoxifen as primary chemotherapy in breast cancer patients. A single institution phase III trial // Proc. Amer. Soc. Clin. Oncol. - 2003. - Vol. 22. - Abstr. 80.
9. Buchholtz T.A., Davis D.W., McConcey D.J. et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy // Cancer (Philad.). - 2003. - Vol. 9. - P. 33-41.
10. Buzdar A.U., Valero V., Theriault R.L. et al. Pathological complete response to chemotherapy is related to hormone receptor status // Proc. Breast Cancer Conf., San Antonio, 2003. - Abstr. 302.
11. Campiglio M., Somenzi G., Ogliati C. et al. Role of proliferation in HER2 status predicted response to doxorubicin // Int. J. Cancer. - 2003. - Vol. 105. - P. 568-573.
12. Chang J.C.N., Wooten E.C., Tsimelzon A. et al. Gene expression patterns for de novo and acquired docetaxel resistance in patients with locally advanced breast cancer // Proc. Amer. Soc. Oncol. - 2003. - Vol. 22, - P. 9 (abstr. 32).
13. Chollet P., Amat S., Cure H et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer // Brit. J. Cancer. - 2002. - Vol. 86. - P. 1041-1046.
14. Clark G.M., Dressler L.G., Owens M.A. et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry // New Engl. J. Med. - 1989. - Vol. 320. - P. 627-633.
15. Clark G.M., Allred D.C., Hilsenbeck S.G. et al. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer // Cancer Res. - 1997. - Vol. 57. - P. 5505-5508.
16. Coon J.S., Marcus E., Gupta-Burt S. et al. Amplification and overexpression of topoisomerase IIa predict response to anthracycline-based therapy in locally advanced breast cancer // Clin. Cancer Res. - 2002. - Vol. 8. - P. 1061-1067.
17. Crowe Jr. J.P., Gordon N.H., Hubay C.A. et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast // Surg. Gynecol. Obstet. - 1991. - Vol. 173. - P. 273-278.
18. De Placido S., De Laurentiis M., Carlomagno C. et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer // Clin. Cancer Res. - 2003. - Vol. 9. - P. 1039-1046.
19. de Witte J.H., Sweep C.G., Klijn J.G. et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients // Brit. J. Cancer. - 1999. - Vol. 79. - P. 1190-1198.
20. Degeorges A., de Roquancourt A., Extra J.M. et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?// Breast Cancer Res. Treat. - 1998. - Vol. 47. - P. 47-55.
21. Del Mastro L., Bruzzi H., Venturini M. et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients // Proc. Amer. Soc. Clin. Oncol. - 2004. - Vol. 23 (abstr. 571).
22. Di Leo A., Chan S., Paesmans M. et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated with either single-agent Doxorubicin or single-agent Docetaxel // Breast Cancer Res. Treat. - 2004. - Vol. 86. - P. 197-206.
23. Eirmann W., Gianni L., Semiglazov V. et al. European cooperative trial in operable breast cancer (ECTO)// Proc. Amer. Soc. Clin. Oncol. - 2003. - Vol. 22 (abstr. 37).
24. Elledge R.M., Green S., Ciocca D. et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study // Clin. Cancer Res. - 1998. - Vol. 4. - P. 7-12.
25. Ellis M., Coop A., Singh B. et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-positive breast cancer // J. Clin. Oncol. - 2001. - Vol. 19. - P. 3808-3816.
26. Esteva F.J., Pusztai L., Symmans W.F. et al. Clinical relevance of HER-2 amplification and overexpression in human cancers // Ref. Gynecol. Obstet. - 2000. - Vol. 7. - P. 267-276.
27. Estevez L.G., Cuevas J.M., Anton A. et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer // Clin. Cancer Res. - 2003. - Vol. 9. - P. 686-692.
28. Faneyte J.F., Schrama J.G., Peterse J.L. et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome // Brit. J. Cancer. - 2003. - Vol. 88. - P. 406-412.
29. Gonzales-Angulo A.M., Krishnamurthy S., Yamamura Y. et al. Lack of association between amplification of her2 and response to preoperative taxanes in patients with breast carcinoma // Cancer (Philad.). - 2004. - Vol. 101. - P. 258-263.
30. Grondahi-Hansen J., Hilsenbeck S.G., Christensen I.J. et al. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients // Breast Cancer Res. Treat. - 1997. - Vol. 43. - P. 153-163.
31. Harbeck N., Meisner C., Prechtl A. et al. Level-1 evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer patients provided by second scheduled analysis of multicenter Chemo-N-0 therapy trial // Breast Cancer Res. Treat. - 2001. - Vol. 89 (abstr. 213).
32. Holmes F.A., Pritsche H.A., Loewy J.W. et al. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay // J. Clin. Oncol. - 1990. - Vol. 8. - P. 1025-1035.
33. Ikeda T., Jinno H., Kitajima M. et al. Chemo sensitivity-related genes of breast cancer detected by DNA microarray // Proc. Amer. Soc. Oncol. - 2003. - Vol. 22. - P. 9 (abstr. 34).
34. Janicke P., Schmitt M., Pache L. et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer // Breast Cancer Res. Treat. - 1993. - Vol. 24. - P. 195-208.
35. Janicke P., Prechtl A., Thomssen C. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 // J. Natl. Cancer Inst. - 2001. - Vol. 93. - P. 913-920.
36. Jarvinen T.A., Kononen J., Pelto-Huikko M. et al. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer // Amer. J. Pathol. - 1996. - Vol. 148. - P. 2073-2082.
37. Kuerer H.M., Newman L.A., Smith T.L. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy // J. Clin. Oncol. - 1999. - Vol. 17. - P. 441-444.
38. Lowe S.W., Ruley H.E., Jacks T. et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents // Cell. - 1993. - Vol. 74. - P. 957-967.
39. Ma X.-J., Wang W., Salunga R. et al. Gene expression signatures assotiated with clinical outcome in breast cancer via laser capture microdissection // Breast Cancer Res. Treat. - 2003. - Vol. 82 (abstr. 29).
40. MacGrogan G., Rudolph P., Mascarel Id.I. et al. DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer // Brit. J. Cancer. - 2003. - Vol. 89. - P. 666-671.
41. Manders P., Beex L.V., Tjan-Heijen V.C. et al. Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients // Int. J. Oncol. - 2004. - Vol. 25. - P. 511-517.
42. McLaughlin R., O'Hanlon D., McHale T. et al. Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer // Int. J. Med. Sci. - 2001. - Vol. 170. - P. 11-13.
43. Muss H.B., Thor A.D., Berry D.A. et al. c-erbB-2 overexpression and response to adjuvant therapy in women with node-positive early breast cancer // New Engl. J. Med. - 1994. - Vol. 330. - P. 1260-1266.
44. Paik S., Bryant J., Park C. et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone-receptor-negative breast cancer // J. Natl. Cancer Inst. - 1990. - Vol. 90. - P. 1361-1370.
45. Penault-Llorca F., Cayre A., Bouchet Mishellany F. et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome // Int. J. Oncol. - 2003. - Vol. 22. - P. 1319-1325.
46. Perou C.M., Sorlie T., Elsen M.B. et al. Molecular portraits of human breast tumours // Nature. - 2000. - Vol. 406. - P. 747-752.
47. Petit T., Borel C., Ghnassia J.P. et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting // Clin. Cancer Res. - 2001. - Vol. 7. - P. 1577-1581.
48. Petit T., Wilt M., Velten M. et al. Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy // Europ. J. Cancer. - 2004. - Vol. 40. - P. 205-211.
49. Poelman S.M., Adeyanju M.O., Robertson M.A. et al. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression // Clin. Cancer Res. - 2000. - Vol. 6. - P. 4043-4048.
50. Pusztai L., Ayers M., Simmans F.W. et al. Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer // Proc. Amer. Soc. Oncol. - 2003. - Vol. 22. - P. 1 (abstr. 1).
51. Pusztai L., Krishnamurthy S., Perez-Cardona J. et al. Expression of BAG-1 and BCL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer // Cancer Invest. - 2004.
52. Ravdin P.M., Green S., Albain K.S. et al. Initial report of the SWOG biological correlative study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone (abstract) // Proc. Amer. Soc. Clin. Oncol. - 1998. - Vol. 17 (abstr. 374).
53. Ravdin P., Olivotto I.A., Speers C. et al. Should estrogen receptor (ER) negativity alone be an indication for chemotherapy in T1N0 breast cancer?// Proc. Amer. Soc. Clin. Oncol. - Ibid. - 2003. - Vol. 22 (abstr. 55).
54. Sataloff D.M., Mason B.A., Prestipino A.J. et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome // J. Amer. Coll Surg. - 1995. - Vol. 180. - P. 297-306.
55. Seidman A.D., Fornier M., Esteva F.J. et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER-2 immunophenotype and gene amplification // J. Clin. Oncol. - 2001. - Vol. 19. - P. 2587-2595.
56. Semiglazov V.F., Zhiltsova E.K., Bozhok A.A. et al. Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients // Europ. J. Cancer. - 2004. - Vol. 40. - P. 71.
57. Sjostrom J., Blomqvist C., Heikkila P. et al. Predictive value of p53, mdm-2, p21 and mib-1 for chemotherapy response in advanced breast cancer // Clin. Cancer Res. - 2000. - Vol. 6. - P. 3103-3110.
58. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene // Science. - 1987. - Vol. 235. - P. 177-182.
59. Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc. Natl. Acad. Sci. USA. - 2001. - Vol. 98. - P. 10869-10874.
60. Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets // Proc. Natl. Acad. Sci. Ibid. - 2003. - Vol. 100. - P. 8418-8423.
61. Stal O., Sullivan S., Wingren S. et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer // Europ. J. Cancer. - 1995. - Vol. 31A. - P. 2185-2190.
62. Sun J.M., Han W., Kim D.W. et al. Clinical relevance of HER-2 expression in node-negative breast cancer patients // Proc. Amer. Soc. Clin. Oncol. - 2004. - Vol. 23.(abstr. 598).
63. Symmans W.F., Ayers M., Clark E.A. et al. Total RNA yield and microarray gene expression profile from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma // Cancer (Philad.). - 2003. - Vol. 97. - P. 2960-2971.
64. Tetu B., Brisson J. Prognostic sognoficance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy // Cancer Ibid. - 1994. - Vol. 73. - P. 2359-2365.
65. Thor A.D., Berry D.A., Budman D.R. et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer // J. Natl. Cancer Inst. - 1998. - Vol. 90. - P. 1346-1360.
66. Thorpe S.M., Rose C., Rasmussen B.B. et al. Steroid hormone receptors as prognostic ondicators in primary breast cancer // Breast Cancer Res. Treat. - 1986. - Vol. 7. - P. 91-98.
67. Untch M., Kahlert S., Moebus V. et al. Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer (BC) - results of a randomized trial // Proc. Amer. Soc. Oncol. - 2003. - Vol. 22 (abstr. 35).
68. Van Noef M.E., Knox W.F., Dhesi S.S. et al. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer // Europ. J. Cancer. - 1993. - Vol. 29A. - P. 1141-1145.
69. Van Poznak C., Tan L., Panageas K.S. et al. Assesment of molecular markers of clinical sensivity to single-agent taxane therapy for metastatic breast cancer // J. Clin. Oncol. - 2002. - Vol. 20. - P. 2319-2326.
70. Van't Veer L.J., Dai H., van de Vijver M.J. et al. Gene expression profiling predicts clinical outcome of breast cancer // Nature. - 2002. - Vol. 415. - P. 530-536.
71. Vincent-Salomon A., Rousseau A., Jouve M. et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline -based preoperative chemotherapy // Europ. J. Cancer. - 2004. - Vol. 40. - P. 1502-1508.
72. Wahl A.F., Donaldson K.L., Fairchild C. et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis // Nat. Med. - 1996. - Vol. 2. - P. 72-79.
73. Weidner N., Semple J.P., Welch W.R. et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma // New Engl. J. Med. - 1991. - Vol. 324. - P. 1-8.
74. Zhang C.C., Yang J.M., Bash-Babula J. et al. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4 // Cancer Res. - 1999. - Vol. 59. - P. 3663-3670.
75. Zhu L., Chow L.W., Loo W.T. et al. Her-2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial // Clin. Cancer Res. - 2004. - Vol. 10. - P. 4639-4644.